Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

(epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC).

-mutated (exon 19 deletion or L858R), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib (in an open-label fashion), osimertinib (in a blinded fashion), or lazertinib (in a blinded fashion, to assess the contribution of treatment components). The primary end point was progression-free survival in the amivantamab-lazertinib group as compared with the osimertinib group, as assessed by blinded independent central review.